Every material Form 8-K Bambusa Therapeutics, Inc. has filed with the SEC since November 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bambusa Therapeutics filed an amended and restated certificate of incorporation with Delaware and adopted amended and restated bylaws on November 2, 2026, in connection with completing its initial public offering. The filing describes these governing documents by reference to its October 30, 2026 prospectus and attaches the full texts as exhibits.
Restated certificate of incorporation filed with the Delaware Secretary of State on November 2, 2026 (Exhibit 3.1)
Restated bylaws adopted effective November 2, 2026 (Exhibit 3.2)
Terms described in the prospectus filed October 30, 2026 under Registration Statement on Form S-1 (File No. 333-299405)
Filing also includes a Regulation FD notice that the company may use its website, social media and other channels to share material information
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bambusa Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →